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LETTER TO THE EDITOR
High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in
the treatment of advanced gastric and oesophageal adenocarcinoma
Sir - Interest in enhancing the activity of 5-Fluorouracil
(5-FU) by the use of prolonged infusions and/or modulation
with high dose folinic acid continues. Early studies showed
an increased response rate and survival benefit in colorectal
adenocarcinoma (Erlichman et al., 1988), but more variable
response rates of 12-48% in advanced gastric adenocar-
cinoma (Machover et al., 1986; Arbuck et al., 1987). Recently
short infusions of high dose folinic acid and 5-FU have
produced response rates of 40% and 43.5% (Johnson et al.,
1991; Louvet et al., 1991).
We have treated 15 patients with advanced histologically
confirmed gastric and oesophageal adenocarcinoma using the
regimen described by De Gramont (De Gramont et al.,
1988). The median age was 62 years (range 52-78) and none
had received previous radiotherapy or chemotherapy. Prior
to the study patients had ECOG performance status values
of less than 2. All patients had disease evaluable by one or
more of the following means; clinical examination, radiology,
ultrasonography, computerised axial tomography or endo-
scopy.
The treatment regimen consisted of folinic acid 200mg
m-2 in 500 ml of N-saline over 2 h followed by 5-FU
400 mgm2 IV bolus then 5-FU 400 mgm-2 in 1000 ml of
N-saline over 22 h. This was repeated on day 2. Oral
mucositis was limited by the prophylactic use of allopurinol
mouthwash, initially hourly for 4 h after the folinic acid
infusion, then four hourly. Laser endoscopy was performed
where necessary for the relief of dysphagia caused by local
disease.
Patients were clinically assessed prior to each cycle and the
evaluable disease formally assessed after six cycles; those with
responding or stable disease continued to a maximum of 12
cycles. Objective response was measured using WHO criteria.
Treatment was stopped at the demonstration of progressive
disease in 14 patients. One patient received a further 2 cycles
after progression on account of marked symptomatic im-
provement. The interval to disease progression and survival
were measured from the start of treatment.
By the time of formal reassessment, 12 weeks after starting
chemotherapy, seven patients (47%) had stable disease, eight
had developed progressive disease, and of these eight, four
had died (Table I). The median interval to progression of
disease was 16 weeks (range 3-23 weeks) and the median
survival 23 weeks (range 4-37 weeks).
Whilst on treatment performance status remained un-
changed in seven patients; six had a reduction of one in their
ECOG score. None gained weight, but twelve reported a
subjective symptomatic improvement after starting 5-FU and
folinic acid. In particular, pain relief (with decreased use of
analgesics) and increased appetite and energy were described.
In total 90 treatment cycles were given (median six per
patient, range 2-10), associated with 26 toxicity reactions.
These were mild and there were no treatment delays nor
dosage reductions. Nine cycles were associated with grade I
to III nausea and vomiting, and four with grade I to III
diarrhoea. Only two episodes of stomatitis were seen (grade I
and IV). Six cycles resulted in grade I white blood cell
suppression and four in mild 'hand/foot' syndrome. One
cycle caused grade I peripheral neurotoxicity.
No responses by WHO criteria were seen in the 15
patients. Using an identical regimen, Johnson (Johnson et al.,
1991) achieved a response rate of 40% (95% CI 10-70%) in
advanced gastric cancer. Similarly, Louvet (Louvet et al.,
1991), using the same regimen but with a 5-FU infusion dose
of 600 mg m-2, reported an overall response rate of 43.5%
(95% CI 23-64%). In comparison, our results in advanced
gastric and oesophageal adenocarcinoma are disappointing.
Yours etc,
M.S. Highley,
M.E. Hill,
N. Ziras,
N. Samandas,
R.C. Mason,
W. Owen,
J. Dussek,
S. Barker,
P.G. Harper
Departments of Oncology and Surgery,
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London SE1 9RT
Table I Response after six cycles of treatment
Primary
site
OE
ST
Assessment
Extent ofdisease after 6 cycles
No. of LAD LAD LAD D LAD +
patients only + LN + D only LN+ D Stable progression
9 0 2 1 1 5 6 3
6 1 2 2 0 1 1 5
OE = Oesophagus. ST = Stomach. LAD = Locally advanced disease. LN = Regional
lymphadenopathy. D = Distant metastases.
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